Novo Nordisk has concluded the acquisition of all outstanding shares of common stock of clinical-stage biopharmaceutical company Forma Therapeutics for $20 for each share in cash or a deal totalling $1.1bn.

In September, Novo Nordisk entered a definitive agreement to acquire Forma.

With the conclusion of the merger, Forma became Novo Nordisk’s fully-owned subsidiary. 

The company noted that Forma’s common stock would not be listed or traded on the Nasdaq Global Select Market any longer.

According to a press statement, Novo Nordisk noted: “Following the finalisation of the tender offer, Novo Nordisk completed the acquisition of Forma through a merger of Novo Nordisk’s wholly owned subsidiary with and into Forma in which all shares not tendered into the offer were cancelled and converted into the right to receive cash equal to the $20 offer price per share, without interest, less any applicable tax withholding.”

Forma works on developing new therapies for patients with sickle cell disease (SCD) and rare blood disorders.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

With the acquisition, Novo Nordisk will gain access to the lead development candidate of Forma, etavopivat.

An oral, investigational, selective pyruvate kinase-R (PKR) activator, etavopivat is in the developmental stage for improving anaemia and red blood cell health in SCD patients. 

Presently, the therapy is in an international Phase II/III Hibiscus clinical trial in SCD patients, as well as a Phase II Gladiolus trial for transfusion-dependent SCD and thalassemia.

The latest takeover is in line with the approach of Novo Nordisk to advance its scientific presence and pipeline in haemoglobinopathies.

During September, Novo Nordisk and Ventus Therapeutics entered an exclusive global licence agreement to develop and market candidates from the latter’s peripherally-restricted NLRP3 inhibitors portfolio.